mk-8507
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02174159)
Timeline
Indications
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N#Cc1cc(Cl)cc(Oc2c(C(F)(F)F)ncn(Cc3cc(C(F)(F)F)c(=O)[nH]n3)c2=O)c1- Mol. weight
- 491.74 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095253 ↗
Also known as
- mk-8507
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07305831 | Phase 1 | Jan 13, 2026 | Merck |
| NCT06891066 | Phase 2 | Apr 14, 2025 | Merck |
| NCT06619678 | Phase 1 | Jan 17, 2024 | Merck |
| NCT05093972 | Phase 1 | Nov 29, 2021 | Merck |
| NCT04564547 | Phase 2 | Mar 9, 2021 | Merck |
| NCT02174159 | Phase 1 | Sep 1, 2014 | Merck |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 6 | 6 | 2 | 2014 |
1 organizations
Page 1 / 1